Horizon Therapeutics PLC (HZNP) News
Filter HZNP News Items
HZNP News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
HZNP News Highlights
- HZNP's 30 day story count now stands at 15.
- Over the past 22 days, the trend for HZNP's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about HZNP are STAR, AG and BMO.
Latest HZNP News From Around the Web
Below are the latest news stories about HORIZON THERAPEUTICS PUBLIC LTD CO that investors may wish to consider to help them evaluate HZNP as an investment opportunity.
Horizon Therapeutics (HZNP) is a Top-Ranked Value Stock: Should You Buy?Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
15 Biggest European Pharmaceutical CompaniesIn this piece, we will take a look at the 15 biggest European pharmaceutical companies. For more companies, head on over to 5 Biggest European Pharmaceutical Companies. Alongside the United States, Europe has some of the most advanced industries and economies in the world. While the Americans are rightly credited with having pioneered the modern […] |
Horizon Therapeutics plc Announces Completion of Enrollment of Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED)DUBLIN, November 16, 2022--Horizon announced that enrollment of its Phase 3 clinical trial (OPTIC-J) in Japan evaluating TEPEZZA for the treatment of active TED is complete. |
Horizon Therapeutics plc Announces Scientific Collaboration with Leading Research Institution to Advance Research in Autoimmunity and InflammationDUBLIN, November 16, 2022--Horizon Therapeutics plc today announced that it has entered a multi-year scientific collaboration with Johns Hopkins University School of Medicine to identify new disease targets and develop therapies for patients with serious autoimmune and inflammatory conditions. The initial focus is the emerging field of immunometabolism, the study of metabolic processes in the body, that when dysregulated, can drive autoimmunity and inflammation. This is the first project in the |
Horizon Therapeutics plc to Participate in Upcoming Investor Healthcare Conferences in NovemberDUBLIN, November 10, 2022--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the following conferences in November: |
Why Horizon Therapeutics Public Limited Company (HZNP) Declined in the Third Quarter?ClearBridge Investments, an investment management company, released its “ClearBridge Select Strategy” third quarter 2022 investor letter. A copy of the same can be downloaded here. The strategy outperformed its benchmark, the Russell 3000 Index, in the third quarter. The strategy’s outperformance in the quarter was attributed to contributions from several smaller-cap, growth-oriented businesses in the consumer […] |
Sustained Patient Response to KRYSTEXXA® (pegloticase) Injection with Methotrexate Compared to KRYSTEXXA Alone Shown through Month 12 in MIRROR Randomized Controlled TrialDUBLIN, November 08, 2022--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that Month 12 data from the MIRROR randomized controlled trial of KRYSTEXXA® (pegloticase) injection with methotrexate will be featured in Plenary I as part of the American College of Rheumatology Convergence 2022. Additional presentations include new imaging analyses describing the effects of urate-lowering therapy on joint health and vascular inflammation for people with chronic gout refractory to conventional t |
Horizon Therapeutics Third Quarter 2022 Earnings: Beats ExpectationsHorizon Therapeutics ( NASDAQ:HZNP ) Third Quarter 2022 Results Key Financial Results Revenue: US$925.4m (down 11% from... |
Data Support the Use of KRYSTEXXA® (pegloticase) Injection with Methotrexate to Treat Uncontrolled Gout in People With Mild-to-Moderate Chronic Kidney DiseaseDUBLIN, November 05, 2022--Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data that indicate KRYSTEXXA (pegloticase) injection with weekly oral methotrexate effectively treats uncontrolled gout without compromising kidney function. These findings are presented as part of the American Society of Nephrology (ASN) Kidney Week, Nov. 3-6, 2022. |
Horizon Therapeutics (HZNP) Receives a Buy from SVB SecuritiesIn a report released today, David Risinger from SVB Securities maintained a Buy rating on Horizon Therapeutics (HZNP - Research Report), with a price target of $88.00. The company's shares closed yesterday at $70.33.According to TipRanks, Risinger is a 4-star analyst with an average return of 13.1% and a 75.00% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Pfizer, Eli Lilly & Co, and Gilead Sciences.In addition to SVB Securities, Horizon Therapeutics also received a Buy from Stifel Nicolaus's Annabel Samimy in a report issued yesterday. However, on November 1, H.C. Wainwright initiated coverage with a Hold rating on Horizon Therapeutics (NASDAQ: HZNP). |